Navigation Links
Formedix to Host Webinar: Discover Define-XML - Practical Uses Today and a Technical Deep Dive on March 14, 2013

Burlington, MA (PRWEB) March 13, 2013

Formedix is launching a series of learning webinars focusing on the everyday issues affecting those within the clinical trial industry including Clinical Data Managers, Standards Directors and Biostatisticians.

On March 14, 2013, Kevin Burges, Technical Business and Standards Director (the company’s very own “Standards Guru”) and CEO, Mark Wheeldon will address questions frequently asked of Formedix regarding Define.xml, combined with real world knowledge and expertise.

Learn about:

  • Creating and re-using Proprietary, CDISC SDTM and ADaM dataset libraries with Define
  • Define-XML: The Myths and the Realities. Your Clinical Trials Automated. Everywhere.
  • Study Start-up: Define-XML aided CRF design & specification process optimization
  • Study Conduct and Analysis: Automated dataset validation with Define.xml
  • The role of Define-XML in Legacy and Proprietary EDC dataset conversions
  • Define-XML 2.0 enhancements: What do they mean to you?
-Define-XML 2.0 enhancements: Technical Deep Dive.

During the webinar, Mark Wheeldon and Kevin Burges will uncover the mystery of this CDISC standard, cover practical uses for Define in the course of an end-to-end clinical trial and, attendees will also have the opportunity to ask questions of the experts at Formedix.

Formedix’s Mark Wheeldon comments that “often Define is ‘churned out’ at the far end as a last gasp submission deliverable and very few people think of managing libraries of all their dataset designs upfront in this vendor neutral standard, or producing detailed dataset specifications for sharing internally or with CROs.” Mr Wheeldon continues, “It is a constant battle to remove the thought of Define as just a submission deliverable. Define-XML creation is becoming more complex and more difficult to produce at the far end, whilst its role is becoming ever more important.” He goes on to say that “Define can be used to represent proprietary EDC, SDTM, and ADaM datasets and describe and map all the data transformation steps of clinical data - from acquisition through to SDTM dataset creation - yet today, Define is one of the most underused and undervalued of all the CDISC standards.”

To register for the webinar, taking place on March 14, 2013, visit the [Registration page.
Sign-up to the Formedix mailing list to be the first to hear about new products, opportunities to meet the company at events and to learn of new upcoming webinars. If you have a suggested topic you would like to see covered, contact us with your ideas.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Formedix Partners with Perceptive Informatics for Forthcoming Webcast, “Four Secrets to Using CDISC Standards to Enable Clinical Trial Efficiencies”
2. "Collaborate to Innovate" with Formedix at DIA Annual Meeting 2012
3. Discovery Labs to Report Fourth Quarter 2012 Results and Hold Conference Call on Wednesday, March 13, 2013
4. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
5. UCSB physicists make discovery in the quantum realm
6. Scientists discover molecule that does double duty in stopping asthma attacks
7. AMRI Promotes Takeshi Yura, Ph.D., to Vice President of Discovery and Development Services, Asia
8. Discovery Labs Receives $30 Million Funding Commitment from Deerfield Management
9. Chicago to Welcome Data Science, Big Data and Data Mining Leaders at the 19th International ACM Knowledge Discovery and Data Mining Conference, KDD 2013
10. Glenmark Announces a New Discovery and the Initiation of IND Enabling Studies of a Novel Monoclonal Antibody Targeting OX40
11. Discovery in synthetic biology takes us a step closer to new industrial revolution
Post Your Comments:
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... While ... machines such as the Cary 5000 and the 6000i models are higher end machines ... is the height of the spectrophotometer’s light beam from the bottom of the cuvette ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):